Skip to main content
Enter your The Contraceptive Pipeline Database username.
Enter the password that accompanies your username.
Progesterone Vaginal Ring (PVR)
Limited Market Approval
A progesterone only 3-month vaginal ring, marketed specifically for breastfeeding women. Progesterone prevents resumption of ovulation and prolongs lactational amenorrhea. Given its short half-life orally, it is destroyed when ingested in mother's milk and there is no impact on the infant.
May 30, 2018
Active Pharmaceutical Ingredient (API):
Potential Multi-Purpose Technology (MPT):
One ring for 3 months
Began discovery in:
Progering (developed by Population Council, CONRAD, UNFPA and Silesia) has been approved for use in Bolivia, Chile, Ecuador, Guatemala, Dominican Republic, El Salvador, Panama, and Peru.
Additional phase III study ongoing in India for submission to Government of India for approval. Additional acceptability studies ongoing in sub-Saharan Africa in preparation for introduction.
It is under evaluation at WHO for the Essential Medicine list and prequalification program at manufacturing site.
Clinical trials have shown high contraceptive efficacy and safety among lactating women; over 98.4% efficacy.
Does not require special infrastructure for storage when not inserted.
Population Council Website
Download Product Report